Novartis AG (NYSE:NVS) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other brokerages also recently weighed in on NVS. Leerink Swann reiterated a “market perform” rating and issued a $83.00 target price on shares of Novartis AG in a report on Thursday, June 22nd. Morgan Stanley upgraded Novartis AG from an “underweight” rating to an “overweight” rating in a report on Wednesday, July 26th. Credit Suisse Group downgraded Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 target price for the company. in a report on Wednesday, July 5th. Cowen and Company reiterated a “hold” rating on shares of Novartis AG in a report on Tuesday, July 18th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a report on Monday, July 17th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $81.71.

Novartis AG (NYSE NVS) traded up 0.12% during mid-day trading on Friday, reaching $84.97. The company had a trading volume of 990,062 shares. The firm’s 50-day moving average is $83.64 and its 200-day moving average is $78.07. Novartis AG has a one year low of $66.93 and a one year high of $86.90. The firm has a market capitalization of $199.08 billion, a P/E ratio of 31.02 and a beta of 0.73.

Novartis AG (NYSE:NVS) last issued its earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.06. The business had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The firm’s revenue for the quarter was down 1.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.23 earnings per share. On average, equities research analysts anticipate that Novartis AG will post $4.75 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/05/novartis-ag-nvs-upgraded-by-bidaskclub-to-hold.html.

In other news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was purchased at an average price of $15.00 per share, for a total transaction of $4,000,005.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.01% of the company’s stock.

Large investors have recently made changes to their positions in the company. Washington Trust Bank increased its stake in shares of Novartis AG by 0.3% in the second quarter. Washington Trust Bank now owns 4,384 shares of the company’s stock valued at $366,000 after buying an additional 14 shares during the period. North Star Investment Management Corp. increased its stake in shares of Novartis AG by 1.0% in the second quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock valued at $129,000 after buying an additional 16 shares during the period. Ledyard National Bank increased its stake in shares of Novartis AG by 0.9% in the second quarter. Ledyard National Bank now owns 3,428 shares of the company’s stock valued at $286,000 after buying an additional 30 shares during the period. Parkside Financial Bank & Trust increased its stake in shares of Novartis AG by 0.7% in the second quarter. Parkside Financial Bank & Trust now owns 4,492 shares of the company’s stock valued at $375,000 after buying an additional 31 shares during the period. Finally, Enterprise Financial Services Corp increased its stake in shares of Novartis AG by 1.7% in the second quarter. Enterprise Financial Services Corp now owns 2,579 shares of the company’s stock valued at $215,000 after buying an additional 42 shares during the period. Institutional investors and hedge funds own 11.28% of the company’s stock.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.